Abstract PD7-10: Neo-n (neon): three-year event-free survival and ultrasensitive ctdna dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin/paclitaxel and nivolumab

Clinical Cancer Research 2026

View at publisher
Authors: S. Loi, Samuel M. Niman, Nicholas Zdenkowski, N. Segui, P. A. Francis, S. Baron Hay, W. Fox, Kevin Punie, A. M. Menzies, Rebecca L. Angus, S. Zardawi, B. Mitchell
+5 more Carlie Mavin, S. Dawson, K. Howarth, M. J. J. Kuper-Hommel, M. M. Regan
DOI: 10.1158/1557-3265.sabcs25-pd7-10
Cited by: 3

Abstract

Abstract Background The Neo-N trial previously showed a pathological complete response (pCR) rate of 53% with 12 weeks of carboplatin/paclitaxel plus nivolumab. We report 3-year EFS and associations of an ultrasensitive tumor-informed structural-variant (SV)–based circulating tumor DNA (ctDNA) assay with EFS. Methods Neo-N is an investigator-initiated, non-comparative, open-label, randomized phase 2 trial across 14 sites. Adults with operable stage I–II TNBC received carboplatin AUC5 q3w + weekly paclitaxel for 12 weeks with nivolumab per assigned schedule- A: lead in monotherapy or B: concurrent Nivolumab, followed by surgery and adjuvant therapy per investigator. A cohort underwent tumor-informed ctDNA SV assay derived from whole genome sequencing and plasma was collected at: T0 (baseline) and T1 (5+/-1 weeks) and T2

Fields of Study & Subjects

Cancer Genomics and Diagnostics Cancer Immunotherapy and Biomarkers PARP inhibition in cancer therapy

Publication details

Journal / source
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Volume
32
Issue
4_Supplement
Pages
PD7–10
Publication date
17 February 2026
Language
EN